Similar articles

• Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome.

  Bakheit AM, Behan PO, Dinan TG, Gray CE, O'Keane V. Bakheit AM, et al. BMJ. 1992 Apr 18;304(6833):1010-2. doi: 10.1136/bmj.304.6833.1010. BMJ. 1992. PMID: 1586780 Free PMC article.
• Increased prolactin response to buspirone in chronic fatigue syndrome.

  Sharpe M, Clements A, Hawton K, Young AH, Sargent P, Cowen PJ. Sharpe M, et al. J Affect Disord. 1996 Nov 4;41(1):71-6. doi: 10.1016/0165-0327(96)00075-4. J Affect Disord. 1996. PMID: 8938208
• Postviral fatigue syndrome.

  Curtis D, Bullock T. Curtis D, et al. BMJ. 1992 Jun 13;304(6841):1566-7. doi: 10.1136/bmj.304.6841.1566-d. BMJ. 1992. PMID: 1628065 Free PMC article. No abstract available.
• Muscle biochemistry and pathophysiology in postviral fatigue syndrome.

  Edwards RH, Newham DJ, Peters TJ. Edwards RH, et al. Br Med Bull. 1991 Oct;47(4):826-37. doi: 10.1093/oxfordjournals.bmb.a072514. Br Med Bull. 1991. PMID: 1794087 Review.
• Dopamine D3 receptors as a therapeutic target for methamphetamine dependence.

  Paterson NE, Vocci F, Sevak RJ, Wagreich E, London ED. Paterson NE, et al. Am J Drug Alcohol Abuse. 2014 Jan;40(1):1-9. doi: 10.3109/00952990.2013.858723. Am J Drug Alcohol Abuse. 2014. PMID: 24359505 Review.